Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibodies Taken From Recovered Coronavirus Patient Could Yield Therapies

Lilly Partners With AbCellera

Executive Summary

Funded by the US government since March 2018, the Vancouver-based company aims to have an antibody therapy ready for clinical trials within four months.

You may also be interested in...



Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest

US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.

Fears Of Recession Mount As Coronavirus Declared A Pandemic

Investor sentiment still backing growth for pharma and biotech sectors, but the length and severity of COVID-19's impact globally has yet to be seen.

Sanofi To Test Arthritis Drug Kevzara For Coronavirus

The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC141834

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel